From: healthline.com Key Takeaways ER-positive breast cancer means cancer cells have estrogen receptors that promote tumor growth when bound to estrogen. It is the most common type of breast cancer. Treatment for ER-positive breast cancer often involves hormone therapy to block estrogen from activating cancer cell growth, and depending on the stage, may also include surgery and chemotherapy. The outlook …
Low-dose megestrol strengthens hormone therapy in ER-positive breast cancer
By: By Dr. Liji Thomas, MD From: news-medical.net Breast cancer causes 670,000 deaths each year, according to the World Health Organization (WHO). About three-fourths of these cancers express estrogen receptors (ER), and these are primarily treated with antiestrogens in the adjuvant and metastatic settings. A recent paper in Nature Cancer reported on the PIONEER study, which examined the effect of …
KAT6 Inhibition Shows Path to Overcoming Resistance Mechanisms in ER+ Breast Cancer
By: Kyle Doherty From: .onclive.com Due to its amplification in approximately 12% to 15% of patients with estrogen receptor (ER)–positive breast cancer and ability to repress ER gene transcription, thereby overcoming ESR1-mediated resistance to endocrine therapy, KAT6 had garnered attention as a therapeutic target of interest in the space.1 “KAT6 is a histone [lysine] acetyltransferase complex,” Sarah Naomi Olsen, PhD, …
Discovery of estrogen receptor ‘switches’ may aid breast cancer treatment
By: Case Western Reserve University From: medicalxpress.com Researchers at Case Western Reserve University School of Medicine have discovered how specific protein regions contribute to breast cancer. Their study, published recently in Nature, focuses on what is known as the estrogen receptor, a protein linked in previous research to the development of roughly 70% of all breast tumors. Just as a …
Navigating the Evolving Landscape of ER-Positive Metastatic Breast Cancer Treatment
By:Alexandra Gerlach From: pharmacytimes.com Key Takeaways CDK4/6 inhibitors improve progression-free survival in ER+ breast cancer but increase adverse events and costs, necessitating careful treatment sequencing. PI3K inhibitors, particularly mutant-selective variants, offer potential in managing ER+ breast cancer, addressing toxicity concerns like hyperglycemia. Antibody-drug conjugates, such as trastuzumab deruxtecan, show promise in ER+ breast cancer, improving response rates but requiring careful …
Key discovery advances fight to reduce breast cancer recurrence
Source: Duke-NUS Medical School From: sciencedaily.com In looking for new ways to fight breast cancer, scientists from Duke-NUS Medical School have unmasked a surprising role of a protein generally associated with cancer growth. They have discovered that in oestrogen receptor-positive (ER+) breast cancer, this protein acts as a tumour suppressor instead. ER+ breast cancer constitutes about 80 per cent of …
Researchers explore gut bacteria’s role in fighting breast cancer
Source: Breast Cancer Now From: news-medical.net Researchers are investigating the function of gut bacteria in breast cancer, and how we could use it to fight against the disease, thanks to new funding from Breast Cancer Now. Bacteria living in our gut can affect our immune system and previous research in other cancers has shown a connection between healthier gut bacteria …
New study advocates for de-escalating breast cancer surgery in women aged 55 and older
Source: University of Pittsburgh From: news-medical.net Surgery involving sentinel lymph node biopsy for middle-aged women with estrogen receptor-positive (ER+) breast cancer may do more harm than good, according to a new study led by University of Pittsburgh and UPMC Hillman Cancer Center researchers. The team used a novel artificial intelligence pipeline developed by Realyze Intelligence, a UPMC Enterprises portfolio company, to analyze electronic …
Scientists Find Potential “Achilles’ Heel” of Drug-Resistant Breast Cancer
From: insideprecisionmedicine.com Researchers at the Baylor College of Medicine have identified a protein called PKMYT1 as a promising marker for a form of drug-resistant breast cancer, as well as a potential drug target for patients that currently face a very poor prognosis. Up to 80 percent of deaths from breast cancer are caused by estrogen receptor-alpha-positive (ER+) tumors. The standard …
Health Canada Approves Goserelin Acetate for High-Risk, ER+ Early and Advanced Breast Cancer
By: Caroline Seymour From: onclive.com Health Canada has approved a supplemental new drug application for goserelin acetate (Zoladex) 10.8 mg every 12 weeks in the management of women with estrogen receptor–positive early breast cancer with a high risk of recurrence or advanced breast cancer in the pre- and perimenopausal setting.1 The approval was based on several global trials that evaluated …